secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2023-02-02T23:59:59+00:00
Accession:  0001628280-23-002037
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology appoints Fairooz Kabbinavar as Chief Medical Officer
---------------------------------------------------------------------

- Annual base salary $480,000, target bonus 45% of base, plus option grant.
- Granted non-qualified option for 425,000 shares at $1.75/share exercise price.
- Options vest over 4 years: 25% after 12 months, then monthly over 36 months.
- Dr. Kabbinavar has 30+ years experience; lead investigator for bevacizumab mCRC approval trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828023002037/0001628280-23-002037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828023002037/crdf-20230202.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-002037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer